NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

SO WHAT: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Equities research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for Novo Nordisk ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

A satirical X post saying the three major insulin manufacturers in the United States had announced 2,000%-3,000% price ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company") (NYSE: NVO) for violations of §§10 (b ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney ...